Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common st
IDEAYA Announces Pricing of Public Offering of Common Stock
09:29pm, Wednesday, 07'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock
Ideaya Biosciences Launches Equity Offering Of $80M
08:01am, Wednesday, 07'th Jul 2021
Ideaya Biosciences Inc (NASDAQ: IDYA) has offered up to $80 million shares in an underwritten public offering. Underwriters have an option to purchase up to $12 million of shares.
IDEAYA Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 06'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80 million of shares of its common stock in a
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
12:26am, Tuesday, 06'th Jul 2021
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
06:00am, Monday, 28'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 28, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev
IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
06:01am, Monday, 24'th May 2021
SOUTH SAN FRANCISCO, Calif., May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and dev
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
08:16am, Monday, 10'th May 2021
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -27.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stoc
SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve
IDEAYA to Participate in Upcoming May 2021 Investor Relations Event
06:00am, Thursday, 06'th May 2021
SOUTH SAN FRANCISCO, Calif., May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021
06:00am, Monday, 19'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and de
SOUTH SAN FRANCISCO, Calif., April 16, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and d
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and de
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors
06:00am, Thursday, 15'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and d
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates
08:20am, Tuesday, 23'rd Mar 2021
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st
